Zusammenfassung
Seit den 1970er-Jahren werden zunehmend Knochenmark- und Stammzelltransplantationen (KMT) durchgeführt. Die therapieassoziierte Letalität hat sich dank verbesserter Transplantationstechniken und supportiver Therapien deutlich reduziert. Jedes Jahr erhalten etwa 50.000 Menschen weltweit Zellen eines Familien- oder Fremdspenders, zunehmend auch nicht komplett HLA-identische Stammzellen. Mit der steigenden Zahl an Langzeitüberlebenden werden verstärkt Folgekrankheiten sichtbar. Dieser Beitrag befasst sich im Wesentlichen mit den Spätkomplikationen der allogenen KMT. Trotz Heilung der malignen Grunderkrankung ist das Gesamtüberleben der transplantierten Patienten verkürzt. Ursachen sind therapieassoziierte Zweitneoplasien, Infektionen und Organdysfunktionen. Als besondere Risikofaktoren gelten eine Ganzkörperbestrahlung, eine chronische Graft-vs.-host-Erkrankung sowie die Behandlung im Kindesalter. Nachsorgeleitlinien wurden erstmals 2006 vorgestellt, 2011 erfolgte ein Update.
Abstract
Since the 1970s there has been an increase in the number of bone marrow and stem cell transplantations as well as a decrease in transplantation-associated fatalities due to improved transplantation techniques and supportive therapy. Annually nearly 50,000 transplantations are conducted worldwide with matched family grafts and matched or sometimes mismatched unrelated donor grafts. The number of long-term survivors is increasing and the late complications of this relatively aggressive therapy are now becoming apparent. This article is essentially concerned with the delayed complications of bone marrow and stem cell transplantations. Despite curing the malignant primary disease the total survival of transplantation patients is reduced. The main reasons are infection, organ dysfunction and therapy-associated secondary neoplasms. Among the high risk factors are total body irradiation, chronic graft versus host disease as well as treatment during childhood. Guidelines for the follow-up care of these long-term survivors were first published in 2006 and then updated in 2011.
Literatur
Deutsches Register für Stammzelltransplantation (DRST) (2013) Jahresbericht 2012
Majhail NS, Rizzo JD, Lee SJ, Aljurf M et al (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47. doi:101038/bmt.2012.5
Wolff D, Bertz H, Greinix H et al (2011) Klinische Versorgung der chronischen Graft-verus-Host-Krankheit: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz. Dtsch Ärztebl Int 108(43):732–740. doi:10.3238/ärztebl.2011.0732
Ljungmann P, Engelhard D, de la Camara R et al (2005) Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35:737–746
Curtis RE, Metyer C, Rizzo JD et al (2005) Impact of chronic GvHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105:3802–3811
Filipovich AH, Wiesdorf D, Pavletic S et al (2005) National Institutes of Health consensus developement project on criteria for clinical trials in chronic graft-versus-host-disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956
Grauer O, Wolff D, Bertz H et al (2010) Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 133:2852–2865
Jacobs R, Tran U, Chen H et al (2012) Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant 47:1470–1473
Detivaud L, Nemeth E, Boudjema K et al (2005) Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106:746–748
Tomas JF, Pinilla I, Garcia-Buey ML et al (2000) Long term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 26:649–655
Jensen PD, Jensen FT, Christensen T et al (2003) Relationship between hepatocellular injury and transfusion iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemia. Blood 101:91–96
Brennan BM, Shalet SM (2002) Endocrine late effects after bone marrow transplant. Br J Haematol 118:58–66
Sanders JE, Hoffmeister PA, Woolfrey AE et al (2009) Thyreoid function follwoing hematopoietic cell transplantation in children: 30 years‘ experience. Blood 113:306–308
Sanders JE (2004) Endocrine complications of high-dose therapy with stem cell transplantation. Pediatr Transplant 8(Suppl 5):39–50
Nakaseko C, Ozawa S, Sakaida E et al (2011) Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol 93:375–382
Au BK, Au Ma, Chien JW (2011) Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17:1072–1078
Holm AM, Riise GC, Hansson L et al (2013) Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant 48:703
Vogl UM, Nagayama K, Bojic M et al (2013) Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation 95:623
Sakaida E, Nakaseko C, Harima A et al (2003) Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 102:4236–4242
Lund MB, Brinch L, Kongerud J, Boe J (2004) Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamid. Eur Resp J 23:901–905
Ditschkowski M, Elmaagacli AH, Koldehoff M et al (2013) Brochiolitis obliterans after allogeneic hematopoetic SCT: further inside-new perspektives? Bone Marrow Transplant 48:1224–1229
Panoskaltsis-Mortari A, Griese M, Madtes DK et al (2011) An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 183:1262
Hingorani S (2006) Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 17:1995–2005
Choi M, Sun CL, Kurian S et al (2008) Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer 113(7):1580–1587
Tichelli A, Bucher C, Rovo A et al (2007) Premature cardiovascular disease after allogeneic hematopoietic stem cell transplantation. Blood 110:3463–3471
Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M (2000) Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 356:993–997
Lorini R, Cortona L, Scaramuzza A et al (1995) Hyperinsulinemia in children and adolescents after bone marrow transplantation. Bone Marrow Transplant 15:873–877
Tomás JF, Pinilla I, Garcia-Bey ML et al (2000) Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 26:649–655
Peffault de Latour R, Levy V, Asselah T et al (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103:1618–1624
Sostak P, Padovan CS, Eigenbrod S et al (2010) Cerebral angiitis in four patients with chronic GvHD. Bone Marrow Transplant 45:1181–1188
Tichelli A, Rovo A, Passweg J et al (2009) Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2:583–601
Curtis RE, Metayer C, Rizzo JD et al (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105:3802–3811
Rizzo JD, Curtis RE, Socie G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175–1183
Metayer C, Curtis RE, Vose J et al (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101:2015–2023
Einhaltung ethischer Richtlinien
Interessenkonflikt. E. Wollmer und A. Neubauer geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wollmer, E., Neubauer, A. Komplikationen der allogenen Knochenmark- und Stammzelltransplantation. Internist 55, 547–561 (2014). https://doi.org/10.1007/s00108-013-3432-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-013-3432-3
Schlüsselwörter
- Allogene Stammzelltransplantation
- Knochenmarktransplantation
- Graft-vs.-host-Erkrankung
- Organdysfunktionen
- Infektionen